About 52North

52North builds medical devices and digital tools that transform emergency cancer care. The Cambridge company develops Neutrocheck, a portable finger prick blood test identifying cancer patients at risk of neutropenic sepsis at home, and ACORN, a digital triage tool for remote management of oncology emergencies. These solutions reduce hospital visits, speed up diagnoses, and improve patient safety. Founded in 2018 as a University of Cambridge spinout, 52North combines diagnostics with artificial intelligence. The patented Aster platform measures multiple biomarkers from a single sample, bringing laboratory diagnostics to point of care and shifting emergency cancer care from reactive hospital attendance to proactive home monitoring.